Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) had its price target cut by equities researchers at Wells Fargo & Company from $18.00 to $17.00 in a report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) had its price target cut by equities researchers at Wells Fargo & Company from $18.00 to $17.00 in a report issued on Monday, Benzinga repo… [+3990 chars]
Related
Share this page
Guest Posts by Easy BranchesGet Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.